A randomized, open-label study of the addition of amantadine to PEGASYS [peginterferon alfa-2a] plus ribavirin on sustained virological response in patients with chronic hepatitis C viral infection who are treatment-naive or have experienced a relapse after treatment with interferon plus ribavirin

Trial Profile

A randomized, open-label study of the addition of amantadine to PEGASYS [peginterferon alfa-2a] plus ribavirin on sustained virological response in patients with chronic hepatitis C viral infection who are treatment-naive or have experienced a relapse after treatment with interferon plus ribavirin

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Jun 2010

At a glance

  • Drugs Amantadine; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 23 Feb 2010 Planned number of patients changed from 500 to 660 as reported by Roche record.
    • 20 Aug 2008 Status change from recruiting to completed according to Roche protocol registry.
    • 20 Jun 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top